Infimab contains Infliximab, a monoclonal antibody used to treat autoimmune diseases. It is a biosimilar of the reference biologic Remicade and works by reducing inflammation in chronic immune-mediated conditions. Infimab is commonly used in patients with diseases like rheumatoid arthritis, Crohn’s disease, and psoriasis when conventional therapies do not work.

Mechanism of Action:

Infliximab works by binding to tumor necrosis factor alpha, a protein in the body that plays a major role in causing inflammation. By blocking TNF alpha, Infimab helps to suppress the abnormal immune response, reduce swelling, and relieve pain and tissue damage in inflammatory diseases.

Uses:

Infimab is prescribed for the treatment of:

• Rheumatoid arthritis in combination with methotrexate

• Ankylosing spondylitis, a form of arthritis affecting the spine

• Psoriatic arthritis and plaque psoriasis

• Crohn’s disease and ulcerative colitis, particularly in moderate to severe cases

• Certain off-label uses in other autoimmune conditions under medical supervision

  Adverse Effects:

  Common side effects:

  • Infusion-related reactions like chills, fever, and itching

  • Headache, nausea, or fatigue

  • Respiratory infections like sinusitis or sore throat